A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia
Lynda D. Roman(University of Southern California), Jeffrey S. Weber(NYU Langone Health), W. Martin Kast(University of Southern California), Juan C. Felix, Sharon P. Wilczynski(City Of Hope National Medical Center), Alexander Burnett(University of Southern California), Laila I. Muderspach(University of Southern California), Joeli Brinkman(University of Miami), M. Aldana(University of Southern California), A. O’Meara(University of Southern California), Grace Facio(University of Southern California)
Cited by 117
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k